Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1345 RSV vaccine in adults aged 60 years and older
jRCT2031220274Completed
- Sponsor
- Moderna Inc
- Start
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Randomised, single-blind trial in respiratory syncytial virus disease (RSV) comparing mRNA-1345 vaccine with Placebo (2 arms). Primary endpoints: Solicited local and systemic adverse reactions up to 7 days postinjection, Unsolicited adverse events up to 28 days postinjection and 3 more. Started Sep 2022; status: completed.
02
Drugs
RNA-100-AR02
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2031220274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220274.